Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

Orlistat (sold as Alli) is one effective over-the-counter weight loss aid that is also FDA-approved.

In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.